The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.

Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

Xenograft Model Antitumor Assays*; Nuclear Proteins/*genetics ; PTEN Phosphohydrolase/*deficiency ; Proto-Oncogene Proteins c-akt/*antagonists & inhibitors ; Pyrimidines/*therapeutic use ; Pyrroles/*therapeutic use ; Stomach Neoplasms/*drug therapy ; Taxoids/*therapeutic use ; Transcription Factors/*genetics; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Asian People ; Cell Line, Tumor ; Cell Proliferation/drug effects ; China ; Disease Models, Animal ; Docetaxel ; Female ; Humans ; Immunohistochemistry ; Mice ; Mice, Nude ; Mutation/genetics ; PTEN Phosphohydrolase/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-akt/metabolism ; Pyrimidines/pharmacology ; Pyrroles/pharmacology ; Stomach Neoplasms/enzymology ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Taxoids/pharmacology ; Treatment Outcome

Introduction: Activation of the PI3K/AKT pathway is a common phenomenon in cancer due to multiple mechanisms, including mutation of PI3KCA, loss or mutation of PTEN, or over-expression of receptor tyrosine kinases. We recently developed a novel AKT kinase inhibitor, AZD5363, and demonstrated that HGC27, a cell line harboring both PI3KCA mutation and PTEN loss, displayed the greatest sensitivity to this AKT inhibitor in vitro and in vivo.
Case Preparation: To further elucidate the correlation between AZD5363 response and genetic alterations in gastric cancer (GC) and identify GC patients with both PI3KCA mutations and PTEN loss, we investigated the effects of pharmacological inhibition of AKT on a panel of 20 GC cell lines and genetic aberrations in tumor samples from a cohort of Chinese GC patients. We demonstrated that GC cells with PI3KCA mutations were selectively sensitive to AZD5363. Disease linkage studies showed that PI3KCA activating mutations or PTEN loss were found in 2.7% (4/150) and 23% (14/61) of Chinese GC patients respectively. To further dissect the role of PI3KCA mutation and PTEN loss in response to AKT inhibition, we tested the antitumor activity of AZD5363 in two patient-derived GC xenograft (PDGCX) models harboring either PI3KCA mutation or PTEN loss. Our data indicated that AZD5363 monotherapy treatment led to a moderate response in the PI3KCA mutant PDGCX model. Whilst monotherapy AZD5363 or Taxotere were ineffective in the PTEN negative PDGCX model, significant anti-tumor activity was observed when AZD5363 was combined with Taxotere.
Conclusion: Our results indicated that PI3KCA mutation is an important determinant of response to AKT inhibition in GC and combination with AZD5363 can overcome innate resistance to Taxotere in a PTEN loss PDGCX model. It is suggested that AKT inhibitor is an attractive option for treatment of a new segment of GC patients with aberrant PI3K/AKT signaling.

Lancet. 2010 Aug 28;376(9742):687-97. (PMID: 20728210)
Mol Cancer Ther. 2012 Apr;11(4):873-87. (PMID: 22294718)
World J Gastroenterol. 2005 Jan 14;11(2):285-8. (PMID: 15633233)
Br J Cancer. 2009 Mar 10;100(5):782-8. (PMID: 19223902)
Tumori. 2005 Nov-Dec;91(6):513-21. (PMID: 16457151)
Exp Hematol. 2002 Dec;30(12):1365-72. (PMID: 12482497)
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064. (PMID: 20238327)
Breast Cancer Res Treat. 2010 Apr;120(2):409-18. (PMID: 19418217)
J Exp Clin Cancer Res. 2010 Apr 16;29:32. (PMID: 20398348)
N Engl J Med. 2001 Sep 6;345(10):725-30. (PMID: 11547741)
Int J Cancer. 2007 Apr 15;120(8):1803-10. (PMID: 17230506)
BMC Cancer. 2012 Feb 01;12:50. (PMID: 22292935)
Br J Cancer. 2012 Mar 13;106(6):1039-44. (PMID: 22343617)
BMC Cancer. 2005 Mar 23;5:29. (PMID: 15784156)
Int J Cancer. 2003 Apr 10;104(3):318-27. (PMID: 12569555)
Anticancer Res. 2011 Dec;31(12):4387-92. (PMID: 22199303)
Am J Pathol. 2012 Aug;181(2):401-12. (PMID: 22705054)
Adv Cancer Res. 2005;94:29-86. (PMID: 16095999)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Cancer Treat Rev. 2013 Feb;39(1):60-7. (PMID: 23102520)
Genes Cancer. 2010 Dec;1(12):1170-7. (PMID: 21779440)
Clin Cancer Res. 2013 Apr 1;19(7):1760-72. (PMID: 23287563)
Int J Cancer. 2005 Nov 10;117(3):376-80. (PMID: 15900596)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
Lab Invest. 2002 Mar;82(3):285-91. (PMID: 11896207)
Eur J Cancer. 2005 Jul;41(11):1649-54. (PMID: 15994075)
Oncologist. 2012;17(3):346-58. (PMID: 22334453)
Clin Cancer Res. 2011 Jun 1;17(11):3542-50. (PMID: 21521776)
Clin Cancer Res. 2009 Mar 1;15(5):1821-9. (PMID: 19223493)

0 (Antineoplastic Agents)
0 (Nuclear Proteins)
0 (PI3KCA protein, human)
0 (Protein Kinase Inhibitors)
0 (Pyrimidines)
0 (Pyrroles)
0 (Taxoids)
0 (Transcription Factors)
15H5577CQD (Docetaxel)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 3.1.3.67 (PTEN Phosphohydrolase)
EC 3.1.3.67 (PTEN protein, human)
WFR23M21IE (capivasertib)

Date Created: 20131004 Date Completed: 20140707 Latest Revision: 20221207

20231215

PMC3850695

10.1186/1479-5876-11-241

24088382